Market recap: RealReal shares jump 44% after IPO

June 30, 2019 at 2:11AM
In this June 5, 2009, photo a woman has Botox injected at Reveal in Arlington, Va. AbbVie is buying Botox maker Allergan in a cash-and-stock deal the drugmakers value at around $63 billion. The maker of the blockbuster immune disorder treatment Humira said Tuesday, June 25, 2019, that it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. (AP Photo/Jacquelyn Martin, File)
AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at around $63 billion. (The Minnesota Star Tribune)

Keeping it real: Secondhand fashion online retailer the RealReal jumped 44% from its IPO price to $28.90 per share Friday on its first day of trading. The company offers a marketplace for discounted Gucci and other luxury goods and trades on the Nasdaq under the "REAL" ticker.

Feeling chipper: Micron Technology shares rose 14.6% to $37.46 Wednesday after the chipmaker reported solid quarterly results and said demand should pick up in the second half of the year. Shares closed the week at $38.59.

Revenue injection: AbbVie fell 14.6% to $67.01 Tuesday after the drug developer said it will pay around $63 billion for Allergan and add the blockbuster Botox to its products. Shares closed Friday at $72.72. Allergan, which surged 27% to $163.95 on the news, closed the week at $167.43.

Tariff jitters: Lennar dropped 6% to $48.31 Tuesday after initially gaining ground on an upbeat earnings report after the homebuilder later said tariffs on Chinese goods were adding an average of $500 to each new home. Shares closed the week at $48.46.

High roller: Caesars surged 16.8.% to $11.67 Monday after Eldorado Resorts said it will buy the casino operator for $17.3 billion in a cash-and-stock deal. The shares closed the week at $11.82. Eldorado, which fell 8.1% to $47.04 on the news, closed Friday at $46.07.

Costly treatment: Pharmaceutical company Bristol-Myers Squibb fell 6.8% to $46 on Monday after it said it would divest the blockbuster psoriasis treatment Otezla to win regulators' approval of its buyout of Celgene. The stock closed Friday at $45.35.

news services

about the writer

about the writer

More from Business

See More
card image
Fairview Health Services

The school is changing an elective course while still working with the Eden Prairie-based health care giant after students raised concerns.

This transmission electron microscope image shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in the lab. (NIAID/TNS) ORG XMIT: 1659810
card image